GlaxoSmithKline bails out of its Fabry deal with Amicus

Slightly less than a year after GlaxoSmithKline ($GSK) and Amicus Therapeutics ($FOLD) reported a failure in their Phase III program for the Fabry disease drug Amigal, the pharma giant has bowed out of the development collaboration. GSK is handing over a check for $3 million to Amicus for a small equity stake and giving up its codevelopment and commercialization rights in exchange for a royalty on any future sales. Report

Suggested Articles

Sixteen years after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.